Result for
Tag: immune
November 3, 2020
Age-Specific Mortality and Immunity Patterns of SARS-CoV-2
Using age-specific COVID-19 death data and seroprevalence studies, the age distribution of deaths among those <65 years old was consistent across 45 countries. The infection fatality ratio (IFR) was estimated to be the lowest among children aged 5-9 years old (0.001%) and increased with age. The highest IFR was observed among those 80+ (8.3%). Mortality…
October 9, 2020
Antibody Responses after COVID-19 Infection in Patients Who Are Mildly Symptomatic or Asymptomatic in Bangladesh
A study of antibody responses after COVID-19 infection in patients in Bangladesh indicated that while people who had mild symptoms generated an immune response, those who had no symptoms had lower antibody levels or did not generate any detectable immune response. IgM and IgA responses developed by day 14 after confirmation of infection in 72%…
Persistence of Serum and Saliva Antibody Responses to SARS-CoV-2 Spike Antigens in COVID-19 Patients
Profiling of IgG, IgA, and IgM antibody response to the SARS-CoV-2 spike protein and its receptor-binding domain (RBD) indicated that anti-SARS-CoV-2 antibody responses were readily detected in serum and saliva from patients with COVID-19, with peak IgG levels occurring 16 to 30 days after symptom onset. IgA and IgM antibodies rapidly decayed over time, although…
August 31, 2020
Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia
Examining both IgG and IgM against multiple SARS-CoV-2 antigens may better inform vaccine studies than focusing on a single antibody. Among patients with lab-confirmed COVID-19 infections, IgM levels increased early after symptom onset for those with either mild (n=15) or severe (n=28) COVID-19 disease, but IgG levels increased early only in those with severe disease….
Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients
Severe adverse events related to transfusion of convalescent plasma were rare (<1%) among a sample of 20,000 adult patients with severe or life-threatening lab-confirmed COVID-19 who received convalescent plasma treatment. A total of 141(<1%) people experienced serious adverse events (SAEs) related to the transfusion of convalescent plasma within four hours of the procedure and an…